Analyst firms · Morgan Stanley · MRTX
Morgan Stanley MRTX price target and rating history
Mirati Therapeutics Inc. (MRTX) · Health Care
Morgan Stanley rates Mirati Therapeutics Inc. (MRTX) Equal-Weight with a $140 price target, as of its latest action on Mar 1, 2022. It has published 4 rating actions on MRTX since August 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Equal-Weight
- Price target
- $140
- Median target, all firms
- Too few
- Actions on MRTX
- 4
Morgan Stanley price target on MRTX
Every Morgan Stanley rating on MRTX
- Mar 1, 2022
- Feb 1, 2022
- Sep 21, 2021
- Aug 26, 2021
Questions about Morgan Stanley and MRTX
- What is Morgan Stanley's price target for MRTX?
- Morgan Stanley's latest stated price target for Mirati Therapeutics Inc. (MRTX) is $140, from its action on Mar 1, 2022.
- What is Morgan Stanley's rating on MRTX?
- Morgan Stanley rates MRTX Equal-Weight, a neutral rating, as of Mar 1, 2022.
- When did Morgan Stanley last change its view on MRTX?
- On Mar 1, 2022, Morgan Stanley cuts its price target to $140 from $150, keeps Equal-Weight.
More MRTX rating histories
All Morgan Stanley ratingsMRTX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.